New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2014
05:27 EDTNVONovo Nordisk reports Q1 EPS down 10% to DKK 2.43
Reports Q1 revenue up 7% in local currencies driven by Levemir and Victoza. Revenue increased by 7% in local currencies and by 2% in Danish kroner to DKK 20.3B. Operating profit increased by 15% in local currencies and by 6% in Danish kroner to DKK 8B.
News For NVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
10:03 EDTNVOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:46 EDTNVONovo Nordisk initiated with a Market Perform at Leerink
Subscribe for More Information
August 20, 2015
11:33 EDTNVOLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
August 14, 2015
10:21 EDTNVONovo Nordisk management to meet with Jefferies
Subscribe for More Information
06:39 EDTNVOGenmab enters commercial license agreement with Novo Nordisk
Genmab (GNMSF) announced it has entered an agreement to grant Novo Nordisk (NVO) commercial licenses to use the DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programs. The bispecific antibodies will target a disease area outside of cancer therapeutics. Under the terms of the agreement, Genmab will receive an upfront payment of $2M from Novo Nordisk. After an initial period of exclusivity for the two target combinations, Novo Nordisk has an option to maintain exclusivity or take the licenses forward on a non-exclusive basis. Genmab is entitled to potential development, regulatory and sales milestones of up to approximately $250M for each exclusive license, or approximately $200M for each non-exclusive license. In addition, Genmab will be entitled to single-digit royalties on sales of any commercialized products.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use